Axogen (AXGN) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axogen (AXGN) has outperformed Neogen (NEOG) over the past year, gaining 110.8% versus a gain of 101.2%. Over five years, AXGN leads with a +165.6% price change compared with -71.5% for NEOG. Neogen is the larger company by market cap ($2.55 billion vs $2.12 billion), about 1.2 times the size, while Axogen is growing revenue faster (+20.2% vs -2.7%).
On valuation, Neogen trades at a lower forward P/E (30.8x vs 52.6x for Axogen). Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -7.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | NEOG |
|---|---|---|
| Share price | $36.18 | $11.71 |
| Market cap | $2.12B | $2.55B |
| 1-day change | +0.39% | +0.26% |
| YTD return | +10.54% | +67.53% |
| 1-year return | +110.84% | +101.20% |
| 5-year return | +165.64% | -71.47% |
| Forward P/E | 52.59 | 30.82 |
| EPS (TTM) | $-0.67 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | $870.40M |
| Revenue growth (YoY) | +20.21% | -2.72% |
| Net income (latest FY) | $-15.70M | $-7.90M |
| Gross margin | 74.31% | 46.93% |
| Operating margin | -3.49% | -2.48% |
| Net margin | -6.97% | -0.91% |
| 52-week high | $52.91 | $14.26 |
| 52-week low | $15.27 | $5.37 |
| Distance from 52-week high | -31.62% | -17.88% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +48.76% | +19.56% |
| Average volume | 1.22M | 3.14M |
| Shares outstanding | 58.67M | 218.11M |
| Employees | 622 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neogen is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -7.0 cents for Axogen.
- Axogen grew revenue faster in its latest fiscal year (+20.21% vs -2.72%).
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
AXGN vs NEOG FAQ
Which is bigger, Axogen or Neogen?
Neogen (NEOG) is larger, with a market capitalization of $2.55B compared with $2.12B for Axogen (AXGN).
Which stock has performed better over the past year, AXGN or NEOG?
AXGN returned +110.84% over the past 12 months, compared with +101.20% for NEOG (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and Neogen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Axogen and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Neogen.